In collaboration with Stanford University, Presentations Highlight Phase 2 Clinical Progress and Mechanistic Insights of BPM31510, a Novel Mitochondrial Modulator Targeting Tumor Metabolism
BOSTON, Mass. — [November 19, 2025] — BPGbio, Inc., a biology-first, AI-powered biopharmaceutical company pioneering mitochondrial and protein homeostasis-based therapeutics, today announced that new clinical and translational data on its investigational therapy BPM31510 for glioblastoma multiforme (GBM) for will be presented at the 2025 World Federation of Neuro-Oncology Societies (WFNOS) and Society for Neuro-Oncology (SNO) Annual Meeting, taking place November 19–23, 2025, in Honolulu, Hawaii.
Researchers from BPGbio and Stanford University will jointly present new insights into the mechanism, efficacy, and biomarker engagement of BPM31510—a lipid nanodispersion of oxidized CoQ10 designed to restore mitochondrial function and reverse tumor metabolic reprogramming in glioblastoma multiforme (GBM), an aggressive and malignant tumor of the brain or spinal cord that carries a very poor survival rate and remains one of the most challenging cancers to treat.
“We have completed enrollment in our Phase 2 glioblastoma trial, and early data demonstrated encouraging signs of activity in patients with newly diagnosed GBM receiving standard chemoradiation, and particularly for unmethylated patients, who face an urgent need for better options,” said Niven R. Narain, Ph.D., President and CEO of BPGbio. “These findings, together with our deep collaborations with leading academic partners such as Stanford, give us confidence as we work closely with clinical trial sites and strategic partners to advance BPM31510 toward market and make a meaningful difference for patients living with GBM.”
Featured Presentations
Trial in Progress (TiP): Interim analysis of a Phase 2 study of BPM31510 (a lipid nanodispersion of oxidized CoQ10) with Vitamin K in combination with standard of care (SOC) RT and TMZ in newly diagnosed glioblastoma patients
Poster Presentation — Saturday, November 22, 11:45 a.m.–1:05 p.m. HST, Exhibit Hall II & III
Presenter: Dr. Poornima Tekumalla, BPGbio Inc.
This ongoing Phase 2 trial (NCT04752813) evaluates BPM31510 with standard chemoradiation in newly diagnosed GBM patients. Interim data demonstrate that BPM31510 is well tolerated, does not exacerbate toxicity of SOC, and shows signals of durable disease control in both methylated and unmethylated MGMT populations. A contemporaneous electronic health record–based control arm is in development to further contextualize survival outcomes.
BPM31510 Engagement of the Warburg Effect in GBM to Therapeutically Modulate Tumor Metabolism Through ROS-Mediated Processes Preclinically and Clinically
Poster Presentation — Saturday, November 22, 11:45 a.m.–1:05 p.m. HST, Exhibit Hall II & III
Presenter: Dr. Stephane Gesta, BPGbio Inc.
Translational research integrating multi-omics, metabolomic imaging, and patient plasma proteomics reveals that BPM31510 reprograms GBM metabolism by restoring mitochondrial respiration, elevating oxidative stress, and downregulating oncogenic signaling—mechanistically reversing the Warburg effect both preclinically and clinically.
A Novel Therapeutic Strategy Using a Single Non-Toxic Agent that Produces Consistent Long-Term Control of Orthotopic Experimental Glioblastomas
Rapid Oral Presentation — Friday, November 21, 11:30 a.m.–12:30 p.m. HST, Exhibit Hall II & III
Poster Presentation — Saturday, November 22, 11:45 a.m.–1:05 p.m. HST, Exhibit Hall II & III
Presenter: Dr. Lawrence Recht, Stanford University
This study highlights BPM31510’s dose-dependent capacity to selectively eradicate tumor cells while sparing healthy brain tissue, resulting in long-term tumor control and apparent cures in 90% of preclinical models. The findings introduce a novel wound-healing–based paradigm for GBM therapy, reframing cancer as a maladaptive failure of tissue repair.
XXXX
Media Contact: Media@bpgbio.com
